NIA Study Confirms Protandim Nrf2 Synergizer Extends Life
August 02 2016 - 9:00AM
A new study sponsored by the NIA ITP and published in Aging Cell
found what developers and users of LifeVantage have held to be true
for a very long time.
As part of the NIA ITP federally-funded program that examines
treatments with the “potential to extend lifespan and delay disease
and dysfunction,” and thereby extend lifespan, researchers provided
the supplement Protandim®, the Nrf2 Synergizer® to male mice in a
rigorous and carefully controlled study. The result: Protandim was
proven to “significantly increase the lifespan of male mice, with a
7 percent increase in median survival.” The findings on female mice
were less dramatically conclusive, showing an increase in lifespan
of 3 percent.
Since the NIA ITP program’s inception in 1999, Protandim is the
only nutritional supplement tested that has been proven to increase
the median survival in mice, thus delaying the aging process.
Protandim was chosen for testing based on positive indications
on its ability to suppress tumor-promoting oxidative stress, cell
proliferation and inflammation, and the ability to protect the
heart from oxidative stress and fibrosis in studies published prior
to 2010. Some of the other recognized nutritional substances tested
included fish oil, curcumin, green tea and resveratrol. None of
these individual ingredients were shown to increase the lifespan of
mice.
“We are extremely excited about these results from the NIA ITP
study and are enthusiastic about the continued advancement of the
research and findings that demonstrate Protandim’s veracity and
effectiveness in additional studies to come,” said LifeVantage
President and Chief Executive Officer Darren Jensen.
For more information about the Protandim results in the NIA’s
study, readers can click here or visit:
http://onlinelibrary.wiley.com/doi/10.1111/acel.12496/abstract.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq:LFVN), is a science based
network marketing company dedicated to visionary science that looks
to transform health, wellness and anti-aging internally and
externally at the cellular level. The company is the maker of the
Protandim® line of scientifically validated dietary supplement, the
TrueScience® Anti-Aging Skin Care Regimen, Canine Health®, the
AXIO® energy product line and the PhysIQ™ smart weight management
system. LifeVantage was founded in 2003 and is headquartered in
Salt Lake City, Utah.
www.lifevantage.com
Forward Looking StatementsThis document
contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words and expressions reflecting optimism, satisfaction or
disappointment with current prospects, as well as words such as
"believe," "hopes," "intends," "estimates," "expects," "projects,"
"plans," "anticipates," "look forward to" and variations thereof,
identify forward-looking statements, but their absence does not
mean that a statement is not forward-looking. Examples of
forward-looking statements include, but are not limited to,
statements we make regarding our future growth and distributor
success. Such forward-looking statements are not guarantees of
performance and the Company's actual results could differ
materially from those contained in such statements. These
forward-looking statements are based on the Company's current
expectations and beliefs concerning future events affecting the
Company and involve known and unknown risks and uncertainties that
may cause the Company's actual results or outcomes to be materially
different from those anticipated and discussed herein. These risks
and uncertainties include, among others, those discussed in greater
detail in the Company's Annual Report on Form 10-K and the
Company's Quarterly Report on Form 10-Q under the caption "Risk
Factors," and in other documents filed by the Company from time to
time with the Securities and Exchange Commission. The Company
cautions investors not to place undue reliance on the
forward-looking statements contained in this document. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this document, except as required by law.
Company Relations Contact:
John Genna (801) 432-9172
Vice President of Communications
& Corporate Partnerships
Investor Relations Contacts:
Cindy England (801) 432-9036
Director of Investor Relations
-Or-
Scott VanWinkle (617) 956-6736
Managing Director, ICR
Lifevantage (NASDAQ:LFVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lifevantage (NASDAQ:LFVN)
Historical Stock Chart
From Apr 2023 to Apr 2024